The UK CMA Phase 1 finding is a procedural step, not a new obstacle, as the remedy is already agreed with the EC. Watch for the CMA's Phase 2 decision or acceptance of the remedy package, which will determine if the early 2027 timeline holds.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $36.41entry
- T+1 · 4d ago +0.41%α +0.78% · $36.56
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
AkzoNobel and Axalta disclosed that the UK CMA's Phase 1 review identified competition concerns solely in UK vehicle refinish coatings. The companies plan to address this with the same remedy package already agreed with the European Commission (divestment of AkzoNobel's European VR coatings business, including the UK). The merger remains on track for early 2027 close.
Key Financial Metrics
Key Facts
- UK CMA Phase 1 decision identifies competition concerns only in UK vehicle refinish coatings
- Companies aim to address with same remedy as European Commission: divestment of AkzoNobel's European VR coatings business including UK
- European Commission already granted conditional approval on Nov 6, 2026
- Merger expected to close early 2027, unchanged from prior guidance
- Combined company would have approximately $17 billion in revenue
Financial Impact
No new financial figures; deal value and terms unchanged from prior filings
Risk Factors
- CMA may require additional or different remedies beyond the EC package, potentially delaying close
- Any delay beyond early 2027 could introduce deal termination risk or renegotiation pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0000950103-26-017306 |
| Document: 0000950103-26-017306-index-headers.html | 0000950103-26-017306 |
| Document: 0000950103-26-017306-index.html | 0000950103-26-017306 |
| Document: 0000950103-26-017306.txt | 0000950103-26-017306 |
Track record
44 reports on AXTA
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +16.39% at T+60 after the Jun 3, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry price pending
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Viewing Entry $36.41 to $36.56 Now $36.56 +0.41% ▲ +0.41% +0.78% vs SPY
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $37.07 to $36.41 Now $36.56 −1.38% ▼ −1.78% −1.43% vs SPY
- Nov 6, 202610d ago 425 Neutral 5/10 Entry $37.53 to $37.38 Now $36.56 −2.58% ▼ −0.40% −0.03% vs SPY
- Nov 6, 202610d ago 425 Bullish 6/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Nov 6, 202610d ago Press Release Bullish 5/10 Entry $36.45 to $37.53 Now $36.56 +0.30% ▲ +2.96% +0.60% vs SPY
- Oct 29, 202618d ago 425 Bearish 4/10 Entry $34.07 to $35.84 Now $36.56 −7.31% ▼ −5.20% −5.67% vs SPY
- Oct 29, 202618d ago 425 Neutral 4/10 Entry $34.07 to $35.84 Now $36.56 +7.31% ▲ +5.20% +5.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers